Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
|
Pre-market 08:05:04 am | ||
| 77.66 USD | +1.38% | 78.28 | +0.79% | |
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
77.65USD
Average target price
90.39USD
Spread / Average Target
+16.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.54% | 96 755 M $ | |
| +59.64% | 525 B $ | |
| +47.97% | 454 B $ | |
| -10.34% | 381 B $ | |
| -6.75% | 262 B $ | |
| -11.26% | 253 B $ | |
| -15.89% | 221 B $ | |
| +2.49% | 202 B $ | |
| -9.2% | 200 B $ | |
| -43.58% | 163 B $ |
- Stock
- Equities
- Stock Gilead Sciences, Inc. - Nasdaq
- News Gilead Sciences, Inc.
- UBS Adjusts Gilead Sciences Price Target to $91 From $90, Maintains Neutral Rating
